Clinical trials: Growth Failure
Failure to Thrive
Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome
This clinical trial will compare the mean first year height velocity of somatropin-treated prepubertal patients with SHOX deficiency with the height velocity of a control group of untreated prepubertal patients with SHOX…
- Trial name
- NCT00190658
- Testing
- Somatropin (rDNA origin) for injection
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Eli Lilly and Company
Noonan Syndrome
Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome
The trial will investigate the treatment of growth failure in children with Noonan syndrome. Abnormalities in the growth hormone (GH) - insulin-like growth factor-I (IGF-I) axis resulting in low IGF-I levels have been suggested…
- Trial name
- NCT00351221
- Testing
- rhIGF-1/rhIGFBP-3
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Insmed Incorporated
Non-small Cell Lung Cancer
A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC
This study was a randomized, controlled, open-label, multicenter phase III clinical study to compare the efficacy and safety of SHR-A2009 with platinum-based dual-agent chemotherapy in patients with EGFR-mutated advanced or…
- Trial name
- NCT06671379
- Testing
- SHR-A2009 monotherapy, platinum-based dual-agent chemotherapy
- Where
- China
- Volunteers
- 498 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Fibromyalgia
Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome
The purpose of this study is to evaluate the efficacy of recombinant human growth hormone (r-hGH) treatment in severe fibromyalgia subjects with growth axis dysfunction.
- Trial name
- NCT00933686
- Testing
- Saizen®
- Where
- Spain
- Volunteers
- 113 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma after failure of…
- Trial name
- NCT03713372
- Testing
- Anti-EGFR monoclonal antibody
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sinocelltech Ltd.
Nonsquamous Non-small Cell Lung Cancer, EGFR L858R
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile.
- Conditions
- Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
- Trial name
- NCT05338970
- Testing
- Patritumab Deruxtecan, Platinum-based chemotherapy
- Where
- 182 sites in United States, Australia and 19 more
- Volunteers
- 586 people
- Sponsor
- Daiichi Sankyo
Carcinoma, Non-Small-Cell Lung
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and…
- Trial name
- MARIPOSA-2 (NCT04988295)
- Testing
- Lazertinib, Amivantamab, Pemetrexed
- Where
- 249 sites in United States, Argentina and 27 more
- Volunteers
- 776 people
- Sponsor
- Janssen Research & Development, LLC
Non-Small Cell Lung Cancer
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
- Trial name
- NCT07100080
- Testing
- Iza-bren, Carboplatin, Cisplatin
- Where
- 187 sites in United States, Argentina and 23 more
- Volunteers
- 500 people
- Sponsor
- Bristol-Myers Squibb
GI Tolerance
The Effects of a High-fiber Formula in Children With Failure to Thrive
The present study is designed to determine the gastrointestinal tolerability of enteral nutritional products, physicians and parents' overall perception of enteral nutrition products as well as providing basic demographic…
- Trial name
- NCT02819401
- Testing
- pediatric formula
- Where
- 17 sites in Turkey (Türkiye)
- Volunteers
- 345 people
- Sponsor
- Abbott Nutrition
Cystic Fibrosis, Failure to Thrive
Clinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished Children
The purpose of this study is to determine whether a nutritional supplement is effective in the treatment of malnutrition in pediatric patients with failure to thrive or cystic fibrosis.
- Conditions
- Cystic Fibrosis, Failure to Thrive, Malnutrition
- Trial name
- VITJUNIOR (NCT02128984)
- Testing
- Symbiotic Formula with DHA and antioxidants, Standard Formula
- Where
- 8 sites in Peru, Spain
- Volunteers
- 109 people
- Sponsor
- Laboratorios Ordesa
Turner Syndrome, Renal Insufficiency, Chronic
Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq
The main purpose of this study is to establish an optimal monitoring regimen in NutropinAq treated children, using newly developed capillary blood spot IGF-1 measurement technology.
- Conditions
- Turner Syndrome, Renal Insufficiency, Chronic, Pituitary Diseases, Dwarfism
- Trial name
- OPTIMA (NCT00234533)
- Testing
- Somatropin (rDNA origin)
- Where
- 45 sites in Belgium, Czechia and 12 more
- Volunteers
- 251 people
- Sponsor
- Ipsen
Diabetic Kidney Disease, Diabetic Nephropathy
A Study in Participants With Diabetic Kidney Disease
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Trial name
- NCT01113801
- Testing
- LY2382770
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company
Advanced or Metastatic NSCLC
Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC
This is a randomized, controlled, open-label, multicenter Phase III clinical study designed to evaluate the efficacy and safety of oral HS-10504 monotherapy versus platinum-based doublet chemotherapy in participants with locally…
- Trial name
- NCT07754123
- Testing
- HS-10504, platinum-based doublet chemotherapy (Pemetrexed and Cisplatin/Carboplatin)
- Volunteers
- 206 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Faltering Growth, Failure to Thrive
Leveraging Optimal Tolerance in Undernourished Infants to Support Growth
The goal of this study is to learn if InfaCore (IC) an energy and nutrient dense formulation (ENDF) can improve growth and tolerance in infants with or at risk of growth faltering when fed IC.
- Trial name
- LOTUS (NCT07549360)
- Testing
- Infant Formula
- Where
- Thailand
- Volunteers
- 35 people
- Sponsor
- Dutch Medical Food
Growth Hormone Deficiency
Sustained Release Formulation of Somatropin (rDNA Origin)for Injection
Annualised height velocity after 12/24 months treatment and HV SDS height velocity after 12/24 months treatment expressed as number of standard deviations difference from the mean population height velocity for the appropriate…
- Trial name
- NCT00600808
- Testing
- BPLG-003
- Volunteers
- 51 people
- Sponsor
- BioPartners GmbH
Pediatric Growth Hormone Deficiency
Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone
This non-interventional study will be performed by design of post-marketing surveillance (PMS) as an additional pharmacovigilance activity of the Risk Management Plan (RMP) for Ngenla® pre-filled pen injection, which is required…
- Trial name
- NCT05509894
- Testing
- Ngenla
- Where
- South Korea
- Volunteers
- 565 people
- Sponsor
- Pfizer
Chronic Renal Insufficiency, End-Stage Renal Disease
A Study in Children With Growth Failure Due to Chronic Renal Insufficiency (CRI) or End Stage Renal Disease (ESRD)
This study is a multicenter, open-label, observational, postmarketing surveillance study that will collect information on the use of Genentech growth hormone (GH) preparations to treat children with CRI in the United States.
- Trial name
- NCT00097617
- Volunteers
- 395 people
- Sponsor
- Genentech, Inc.
Growth Hormone Deficiency (GHD)
Treatment of Children With Insufficient Secretion of Growth Hormone
The purpose of this study is to compare a new weekly administered growth hormone preparation with standard daily treatment in children with insufficient secretion of growth hormone
- Trial name
- BPLG-004 (NCT00271518)
- Testing
- growth hormone (somatropin)
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- LG Life Sciences
Faltering Growth
Intervention Study to Investigate the Effects of ONS Use Among Malaysian Children With Faltering Growth
A randomised, open label, controlled intervention study to test the effect of the test product with dietary counselling versus dietary counselling alone on Weight-for-Age z-score change in children from ≥ 1 to ≤ 6 years of age…
- Trial name
- MONS (NCT05193630)
- Testing
- Milnutri Sure™
- Where
- Malaysia
- Volunteers
- 172 people
- Sponsor
- Danone Specialized Nutrition (M) Sdn Bhd
Hospitalized Cases of Angioneurotic Oedema, Pneumonia
Drug Utilization and Safety Events Among Children Using Esomeprazole, Other Proton Pump Inhibitors or H2-receptor Antagonists
The purpose of this study is 1. To describe patient characteristics and drug usage among children that are prescribed esomeprazole for the first time and to compare them with patients who are prescribed other proton pump…
- Conditions
- Hospitalized Cases of Angioneurotic Oedema, Pneumonia, Gastroenteritis, Failure to Thrive
- Trial name
- NCT01338363
- Where
- Netherlands
- Volunteers
- 23,470 people
- Sponsor
- AstraZeneca